Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in children and adolescents: Selective reactions

Journal of Investigational Allergology and Clinical Immunology

Volumn 25, Issue 6, 2015, Pages 385-395

  Blanca Lopez N ^a   Cornejo Garcia J A ^b   Perez Alzate D ^a   Perez Sanchez N ^b   Plaza Seron M C ^b   Dona I ^b   Torres, M J ^b   Canto, G ^a   Kidon, M ^c,d   Perkins, J R ^b   Blanca, M ^b  

^a HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c SHEBA MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Drug hypersensitivity reactions; Induced delayed reactions; Induced urticaria angioedema or anaphylaxis; Nsaids; Single nsaid

Indexed keywords

IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISOLONE; PYRAZOLONE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; DESENSITIZATION; DIFFERENTIAL DIAGNOSIS; DRESS SYNDROME; DRUG HYPERSENSITIVITY; HUMAN; HYPEREOSINOPHILIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; PATCH TEST; PATHOPHYSIOLOGY; PHOTOALLERGY; PROVOCATION TEST; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VIRUS INFECTION; ADOLESCENT; CHILD; RISK FACTOR;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; DIAGNOSIS, DIFFERENTIAL; DRUG HYPERSENSITIVITY; HUMANS; RISK FACTORS;

EID: 84950319413     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Conaghan PG. A turbulent decade for NSAIDs: update oncurrent concepts of classification, epidemiology, comparativeefficacy, and toxicity. Rheumatol Int. 2012;32:1491-502
2. Rawlins MDTW. Mechanisms of adverse drug reactions. In: Davies DM ed. Textbook of adverse drug reactions. New York,NY, Oxford University Press. 1991:18-45
3. Torres MJ, Barrionuevo E, Kowalski M, Blanca M. Hypersensitivity reactions to nonsteroidal anti-inflammatorydrugs. Immunol Allergy Clin North Am. 2014;34:507-24
4. Solensky RM, L.M. Drug allergy. In: Leung DYM , SampsonHA, Geha R, Szefler SJ, eds. Pediatric Allergy, Principles andpractice 2nd edn. St Louis: Mosby Elsevier. 2010;616-30
5. Eustace N, O'Hare B. Use of nonsteroidal anti-inflammatorydrugs in infants. A survey of members of the Association ofPaediatric Anaesthetists of Great Britain and Ireland. PaediatrAnaesth. 2007;17:464-9
6. Neubert A, Verhamme K, Murray ML, Picelli G, Hsia Y, Sen FE, Giaquinto C, Ceci A, Sturkenboom M, Wong IC, ExcellenceT No. The prescribing of analgesics and non-steroidal antiinflammatorydrugs in paediatric primary care in the UK, Italyand the Netherlands. Pharmacol Res. 2010;62:243-8
7. Valkhoff VE, Schade R, t Jong GW, Romio S, Schuemie MJ, Arfe A, Garbe E, Herings R, Lucchi S, Picelli G, Schink T, Straatman H, Villa M, Kuipers EJ, Sturkenboom MC. Population-basedanalysis of non-steroidal anti-inflammatory drug use amongchildren in four European countries in the SOS project: whatsize of data platforms and which study designs do we need toassess safety issues? BMC Pediatr. 2013;13:192
8. Cornejo-Garcia JA, Blanca-Lopez N, Dona I, Andreu I, Agundez JA, Carballo M, Blanca M, Canto MG. Hypersensitivityreactions to non-steroidal anti-inflammatory drugs. Curr DrugMetab. 2009;10:971-80
9. Canto MG, Andreu I, Fernandez J, Blanca M. Selectiveimmediate hypersensitivity reactions to NSAIDs. Curr OpinAllergy Clin Immunol. 2009;9:293-7
10. Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, Rosado A, Rondon C, Campo P, Agundez JA, Blanca M, Canto G. Characteristics of subjects experiencinghypersensitivity to non-steroidal anti-inflammatory drugs:patterns of response. Clin Exp Allergy. 2011;41:86-95
11. Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F, Salas M, Rondon C, Canto MG, Blanca M. Drug hypersensitivity reactions: response patterns, druginvolved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol. 2012;22:363-71
12. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, Brockow K, Campo P, Celik G, Cernadas J, Cortellini G, Gomes E, Nizankowska-Mogilnicka E, Romano A, Szczeklik A, Testi S, Torres MJ, Wohrl S, Makowska J. Classification and practical approach to the diagnosisand management of hypersensitivity to nonsteroidal antiinflammatorydrugs. Allergy. 2013;68:1219-32
13. Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, Bousquet P, Celik G, Demoly P, Gomes ER, Nizankowska-Mogilnicka E, Romano A, Sanchez-Borges M, Sanz M, Torres MJ, De Weck A, Szczeklik A, Brockow K. Hypersensitivity to nonsteroidal anti-inflammatory drugs(NSAIDs) -classification, diagnosis and management:review of the EAACI/ENDA and GA2LEN/HANNA. Allergy.2011;66:818-29
14. Pichler WJ. Delayed drug hypersensitivity reactions. Ann InternMed. 2003;139:683-93
15. Shiohara T, Kano Y. A complex interaction between drug allergyand viral infection. Clin Rev Allergy Immunol. 2007;33:124-33
16. Sanchez-Borges M, Capriles-Behrens E, Caballero-Fonseca F. Hypersensitivity to non-steroidal anti-inflammatory drugs inchildhood. Pediatr Allergy Immunol. 2004;15:376-80
17. Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison between paediatric and adultsuspected adverse drug reactions reported to the Europeanmedicines agency: implications for pharmacovigilance. Paediatr Drugs. 2014;16:309-19
18. Asero R. Oral aspirin challenges in patients with a history ofintolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy. 2005;35:713-6
19. Quiralte J, Blanco C, Delgado J, Ortega N, Alcntara M, Castillo R, Anguita JL, Saenz de San Pedro B, Carrillo T. Challenge-basedclinical patterns of 223 Spanish patients with nonsteroidalanti-inflammatory-drug-induced-reactions. J Investig AllergolClin Immunol. 2007;17:182-8
20. Zambonino MA, Torres MJ, Munoz C, Requena G, Mayorga C, Posadas T, Urda A, Blanca M, Corzo JL. Drug provocation testsin the diagnosis of hypersensitivity reactions to non-steroidalanti-inflammatory drugs in children. Pediatr Allergy Immunol.2013;24:151-9
21. Khaled A, Kharfi M, Ben Hamida M, El Fekih N, El Aidli S, Zeglaoui F, Ezzine N, Fazaa B, Kamoun MR. Cutaneous adversedrug reactions in children. A series of 90 cases. Tunis Med.2012;90:45-50
22. Heelan K, Shear NH. Cutaneous drug reactions in children: anupdate. Paediatr Drugs, 2013;15:493-503
23. Noguera-Morel L, Hernandez-Martin A, Torrelo A. Cutaneousdrug reactions in the pediatric population. Pediatr Clin NorthAm. 2014;61:403-26
24. Mayorga C, Torres MJ, Fernandez J, Canto G, Blanca M. Cutaneous symptoms in drug allergy: what have we learnt? Curr Opin Allergy Clin Immunol. 2009;9:431-6
25. Castell JV, Castell M. Allergic hepatitis induced by drugs. CurrOpin Allergy Clin Immunol. 2006;6:258-65
26. Goodwin SD, Glenny RW. Nonsteroidal anti-inflammatory drugassociatedpulmonary infiltrates with eosinophilia. Review ofthe literature and Food and Drug Administration Adverse DrugReaction reports. Arch Intern Med. 1992;152:1521-4
27. Squires RH, Jr., Shneider BL, Bucuvalas J, Alonso E, Sokol RJ, Narkewicz MR, Dhawan A, Rosenthal P, Rodriguez-Baez N, Murray KF, Horslen S, Martin MG, Lopez MJ, Soriano H, McGuire BM, Jonas MM, Yazigi N, Shepherd RW, Schwarz K, Lobritto S, Thomas DW, Lavine JE, Karpen S, Ng V, Kelly D, Simonds N, Hynan LS. Acute liver failure in children: the first348 patients in the pediatric acute liver failure study group. JPediatr. 2006;148:652-8
28. Porto Arceo JA. Special features of NSAID intolerance inchildren. Allergol Immunopathol (Madr). 2003;31:109-25
29. Auriel E, Regev K, Korczyn AD. Nonsteroidal anti-inflammatorydrugs exposure and the central nervous system. Handb ClinNeurol. 2014;119:577-84
30. Rodriguez-Pena R, Antunez C, Martin E, Blanca-Lopez N, Mayorga C, Torres MJ. Allergic reactions to beta-lactams. Expert Opin Drug Saf. 2006;5:31-48
31. Diaz Jara M, Perez Montero A, Gracia Bara MT, Cabrerizo S, Zapatero L, Martinez Molero MI. Allergic reactions due toibuprofen in children. Pediatr Dermatol. 2001;18:66-7
32. Hassani A, Ponvert C, Karila C, Le Bourgeois M, De Blic J, Scheinmann P. Hypersensitivity to cyclooxygenase inhibitory drugsin children: a study of 164 cases. Eur J Dermatol. 2008;18:561-5
33. Kidon MI, Kang LW, Chin CW, Hoon LS, See Y, Goh A, Lin JT, Chay OM. Early presentation with angioedema andurticaria in cross-reactive hypersensitivity to nonsteroidalantiinflammatory drugs among young, Asian, atopic children. Pediatrics. 2005;116:e675-80
34. Couto M, Gaspar A, Morais-Almeida M. Selective anaphylaxisto paracetamol in a child. Eur Ann Allergy Clin Immunol.2012;44:163-6
35. Ozkaya-Bayazit E. Specific site involvement in fixed drugeruption. J Am Acad Dermatol. 2003;49:1003-7
36. Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Drug relatedclinical pattern in fixed drug eruption. Eur J Dermatol.2000;10:288-91
37. Sarkar R, Kaur C, Kanwar AJ. Extensive fixed drug eruption tonimesulide with cross-sensitivity to sulfonamides in a child. Pediatr Dermatol. 2002;19:553-4
38. Belhadjali H, Ghannouchi N, Njim L, Mohamed M, Moussa A, Bayou F, Chakroun M, Zakhama A, Zili J. Acute generalizedexanthematous pustulosis induced by bufexamac in an atopicgirl. Contact Dermatitis. 2008;58:247-8
39. Babala J, Brozman M, Blazovsky J. Lyell's syndrome: histological,immunohistochemical and serological observations. ActaPaediatr Acad Sci Hung. 1976;17:9-15
40. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, Martin E, Kaufman DW, Maison P. Medicationsas risk factors of Stevens-Johnson syndrome and toxicepidermal necrolysis in children: a pooled analysis. Pediatrics.2009;123:e297-304
41. Andreu I, Mayorga C, Miranda MA. Generation of reactiveintermediates in photoallergic dermatitis. Curr Opin AllergyClin Immunol. 2010;10:303-8
42. Guillaume JC, Roujeau JC, Chevais M, Albengres E, Revuz J, Touraine R. Lyell's syndrome and ectodermosis pluriorificialisduring treatment with oxicams: 11 cases. Ann DermatolVenereol. 1985;112:807-12
43. Serrano G, Fortea JM, Latasa JM, Millan F, Janes C, Bosca F, Miranda MA. Photosensitivity induced by fibric acid derivativesand its relation to photocontact dermatitis to ketoprofen. J AmAcad Dermatol. 1992;27:204-8
44. Diaz RL, Gardeazabal J, Manrique P, Raton JA, Urrutia I, Rodriguez-Sasiain JM, Aguirre C. Greater allergenicity oftopical ketoprofen in contact dermatitis confirmed by use. Contact Dermatitis. 2006;54:239-43
45. Torres MJ, Corzo JL, Leyva L, Mayorga C, Garcia-Martin FJ, Antunez C, Posadas S, Jurado A, Blanca M. Differences inthe immunological responses in drug- and virus-inducedcutaneous reactions in children. Blood Cells Mol Dis.2003;30:124-31
46. Pavlos R, Mallal S, Ostrov D, Pompeu Y, Phillips E. Fever, rash, and systemic symptoms: understanding the role of virus andHLA in severe cutaneous drug allergy. J Allergy Clin ImmunolPract. 2014;2:21-33
47. Mayorga C, Pena RR, Blanca-Lopez N, Lopez S, Martin E, Torres MJ. Monitoring the acute phase response in non-immediateallergic drug reactions. Curr Opin Allergy Clin Immunol.2006;6:249-57
48. Lai M, Huang YC, Yao PC. Tissue necrosis after intramuscularadministration of diclofenac: report of one case. Acta PaediatrTaiwan. 2005;46:24-6
49. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associatedacute-onset vanishing bile duct and Stevens-Johnsonsyndromes in a child. Gastroenterology. 1998;115:743-6
50. Faulkner L, Meng X, Park BK, Naisbitt DJ. The importance ofhapten-protein complex formation in the development of drugallergy. Curr Opin Allergy Clin Immunol. 2014;14:293-300
51. Meng X, Jenkins RE, Berry NG, Maggs JL, Farrell J, Lane CS, Stachulski AV, French NS, Naisbitt DJ, Pirmohamed M, Park BK. Direct evidence for the formation of diastereoisomericbenzylpenicilloyl haptens from benzylpenicillin andbenzylpenicillenic acid in patients. J Pharmacol Exp Ther.2011;338:841-9
52. Meng X, Howarth A, Earnshaw CJ, Jenkins RE, French NS, Back DJ, Naisbitt DJ, Park BK. Detection of drug bioactivation invivo: mechanism of nevirapine-albumin conjugate formationin patients. Chem Res Toxicol. 2013;26:575-83
53. Kretz-Rommel A, Boelsterli UA. Diclofenac covalent proteinbinding is dependent on acyl glucuronide formation and isinversely related to P450-mediated acute cell injury in culturedrat hepatocytes. Toxicol Appl Pharmacol. 1993;120:155-61
54. Ikegawa S, Isriyanthi NM, Nagata M, Yahata K, Ito H, Mano N, Goto J. The enantioselective immunoaffinity extraction ofan optically active ibuprofen-modified peptide fragment. AnalBiochem. 2001;296:63-72
55. Zhu D, Becker WM, Schulz KH, Schubeler K, Schlaak M. Thepresence of specific IgE to salicyloyl and O-methylsalicyloylin aspirin-sensitive patients. Asian Pac J Allergy Immunol.1992;10:25-32
56. Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, Suau R. Angioedema and IgE antibodies to aspirin: a casereport. Ann Allergy. 1989;62:295-8
57. Zhu DX, Zhao JL, Mo L, Li HL. Drug allergy: identificationand characterization of IgE-reactivities to aspirin and relatedcompounds. J Investig Allergol Clin Immunol. 1997;7:160-8
58. Daxun Z, Becker WM, Schulz KH, Schlaak M. Sensitivity toaspirin: a new serological diagnostic method. J InvestigAllergol Clin Immunol. 1993;3:72-8
59. Zhu D, Becker WM, Schulz KH, Schubeler K, Schlaak M. Detection of IgE antibodies specific for 1-phenyl-2,3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic methodfor sensitivity to pyrazoline drugs. Asian Pac J Allergy Immunol.1992;10:95-101
60. Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J,Poniatowska M. Diagnosis of pyrazolone drug sensitivity:clinical history versus skin testing and in vitro testing. AllergyAsthma Proc. 1999;20:347-52
61. Ariza AT, Torres MJ, García-Martín E, Montañez MI, Agúndez JAG, Mayorga C, Doña I, Blanca-Lopez N, Zambonino MA, Andreu I, Blanca M. Basophil activation test with dipyronemetabolites in the evaluation of immediate allergic reactionsto dipyrone. Allergy. 2014;69 (Suppl 99):133-276
62. Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, Blanca M, Mayorga C. Immunoglobulin E-mediatedimmediate allergic reactions to dipyrone: value of basophilactivation test in the identification of patients. Clin Exp Allergy. 2009;39:1217-24.
63. Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, Ebner H, Ebner C. IgE-mediatedimmediate-type hypersensitivity to the pyrazolone drugpropyphenazone. J Allergy Clin Immunol. 2003;111:882-8
64. Sen I, Mitra S, Gombar KK. Fatal anaphylactic reaction to oraldiclofenac sodium. Can J Anaesth. 2001;48:421
65. van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG. Different risks for NSAID-induced anaphylaxis. AnnPharmacother. 2002;36:24-9
66. Picaud J, Beaudouin E, Renaudin JM, Pirson F, Metz-Favre C, Dron-Gonzalvez M, Moneret-Vautrin DA. Anaphylaxisto diclofenac: nine cases reported to the Allergy VigilanceNetwork in France. Allergy. 2014;69:1420-3
67. Harrer A, Lang R, Grims R, Braitsch M, Hawranek T, Aberer W, Vogel L, Schmid W, Ferreira F, Himly M. Diclofenachypersensitivity: antibody responses to the parent drug andrelevant metabolites. PLoS One. 2010;5:e13707
68. Morelli JG, Tay YK, Rogers M, Halbert A, Krafchik B, Weston WL. Fixed drug eruptions in children. J Pediatr. 1999;134:365-7
69. Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Druginducedhypersensitivity syndrome: drug reaction witheosinophilia and systemic symptoms (DRESS) syndromeinduced by aspirin treatment of Kawasaki disease. J Am AcadDermatol. 2009;60:146-9
70. Pliskow S. Severe gynecologic sequelae of Stevens-Johnsonsyndrome and toxic epidermal necrolysis caused by ibuprofen:a case report. J Reprod Med. 2013;58:354-6
71. Sheridan RL, Schulz JT, Ryan CM, Schnitzer JJ, Lawlor D, Driscoll DN, Donelan MB, Tompkins RG. Long-term consequences of toxicepidermal necrolysis in children. Pediatrics. 2002;109:74-8
72. Ferrandiz-Pulido C, Garcia-Fernandez D, Dominguez-Sampedro P, Garcia-Patos V. Stevens-Johnson syndromeand toxic epidermal necrolysis in children: a review of theexperience with paediatric patients in a university hospital. JEur Acad Dermatol Venereol. 2011;25:1153-9
73. Assem ES. Immunological and non-immunologicalmechanisms of some of the desirable and undesirable effectsof anti-inflammatory and analgesic drugs. Agents Actions.1976;6:212-18
74. Gomez E, Blanca-Lopez N, Salas M, Canto G, Campo P, Torres MJ, Mayorga C, Blanca M. Induction of accelerated reactionsto amoxicillin by T-cell effector mechanisms. Ann AllergyAsthma Immunol. 2013;110:267-73
75. Moreno-Ancillo A, Gil-Adrados AC, Jurado-Palomo J. Ibuprofen-induced aseptic meningoencephalitis confirmed bydrug challenge. J Investig Allergol Clin Immunol. 2011;21:484-7
76. Inoue M, Horita N, Kimura N, Kojima R, Miyazawa N. Threecases of mesalazine-induced pneumonitis with eosinophilia.Respir Investig. 2014;52:209-12
77. Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J, Demoly P, Bousquet PJ, Merk HF, Sanz ML, Ott H, Atanaskovic-Markovic M. Update on the evaluationof hypersensitivity reactions to betalactams. Allergy.2009;64:183-93
78. Blanca M, Torres MJ, Garcia JJ, Romano A, Mayorga C, deRamon E, Vega JM, Miranda A, Juarez C. Natural evolutionof skin test sensitivity in patients allergic to beta-lactamantibiotics. J Allergy Clin Immunol. 1999;103:918-24
79. Torres MJ, Mayorga C, Fernandez TD, Cornejo-Garcia JA, Antunez C, Valenzuela M, Del Prado MF, Rodriguez-Pena R, Blanca M. T cell assessment in allergic drug reactions duringthe acute phase according to the time of occurrence. Int JImmunopathol Pharmacol. 2006;19:119-30
80. Nettis E, Giordano D, Colanardi MC, Paradiso MT, Ferrannini A, Tursi A. Delayed-type hypersensitivity rash from ibuprofen. Allergy. 2003;58:539-40
81. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a studyof 450 cases. Int J Dermatol. 1998;37:833-8
82. Shiohara T, Mizukawa Y. Fixed drug eruption: a diseasemediated by self-inflicted responses of intraepidermal T cells. Eur J Dermatol. 2007;17:201-8
83. Roujeau JC, Stern RS. Severe adverse cutaneous reactions todrugs. N Engl J Med. 1994;331:1272-85
84. Um SJ, Lee SK, Kim YH, Kim KH, Son CH, Roh MS, Lee MK. Clinical features of drug-induced hypersensitivity syndrome in38 patients. J Investig Allergol Clin Immunol. 2010;20:556-62
85. Lee JH, Park HK, Heo J, Kim TO, Kim GH, Kang DH, Song GA, Cho M, Kim DS, Kim HW, Lee CH. Drug Rash with Eosinophiliaand Systemic Symptoms (DRESS) syndrome induced bycelecoxib and anti-tuberculosis drugs. J Korean Med Sci.2008;23:521-5
86. Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome):a reappraisal. Br J Dermatol. 1979;100:69-86
87. Correia O, Delgado L, Barbosa IL, Campilho F, Fleming-Torrinha J. Increased interleukin 10, tumor necrosis factor alpha, andinterleukin 6 levels in blister fluid of toxic epidermal necrolysis. J Am Acad Dermatol. 2002;47:58-62
88. Miyauchi H, Hosokawa H, Akaeda T, Iba H, Asada Y. T-cellsubsets in drug-induced toxic epidermal necrolysis. Possiblepathogenic mechanism induced by CD8-positive T cells. ArchDermatol. 1991;127:851-5
89. Paquet P, Pierard GE. Soluble fractions of tumor necrosisfactor-alpha, interleukin-6 and of their receptors in toxicepidermal necrolysis: a comparison with second-degree burns. Int J Mol Med. 1998;1:459-62
90. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition oftoxic epidermal necrolysis by blockade of CD95 with humanintravenous immunoglobulin. Science. 1998;282:490-3
91. Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M. Delayed reactionsto drugs show levels of perforin, granzyme B, and Fas-Lto be related to disease severity. J Allergy Clin Immunol.2002;109:155-61
92. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, Boumsell L, Bensussan A, Roujeau JC. Evaluation ofthe potential role of cytokines in toxic epidermal necrolysis. JInvest Dermatol. 2004;123:850-5
93. Tohyama M, Hashimoto K. Immunological mechanisms ofepidermal damage in toxic epidermal necrolysis. Curr OpinAllergy Clin Immunol. 2012;12:376-82
94. Edell DS, Davidson JJ, Muelenaer AA, Majure M. Unusualmanifestation of Stevens-Johnson syndrome involving therespiratory and gastrointestinal tract. Pediatrics. 1992;89:429-32
95. Carbone C, Rende P, Comberiati P, Carnovale D, Mammi M, DeSarro G. The safety of ketoprofen in different ages. J PharmacolPharmacother. 2013;4:S99-S103
96. Fernandez TD, Torres MJ, Blanca-Lopez N, Rodriguez-Bada JL, Gomez E, Canto G, Mayorga C, Blanca M. Negativizationrates of IgE radioimmunoassay and basophil activation test inimmediate reactions to penicillins. Allergy. 2009;64:242-8
97. Aranda A, Mayorga C, Ariza A, Dona I, Blanca-Lopez N, Canto G, Blanca M, Torres MJ. IgE-mediated hypersensitivityreactions to methylprednisolone. Allergy. 2010;65:1376-80
98. Moreno F, Blanca M, Mayorga C, Terrados S, Moya M, Perez E, Suau R, Vega JM, Garcia J, Miranda A, et al. Studies of thespecificities of IgE antibodies found in sera from subjects withallergic reactions to penicillins. Int Arch Allergy Immunol.1995;108:74-81
99. Bochenek G, Nizankowska E, Szczeklik A. The atopy trait inhypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 1996;51:16-23
100. Kemp SF, Lockey RF. Anaphylaxis: a review of causes andmechanisms. J Allergy Clin Immunol. 2002;110:341-8
101. Simons FE. 9. Anaphylaxis. J Allergy Clin Immunol.2008;121:S402-7
102. Pirmohamed M. Personalized pharmacogenomics: predictingefficacy and adverse drug reactions. Annu Rev Genomics HumGenet. 2014;15:349-70
103. Ponvert C. Allergic and non-allergic hypersensitivity tonon-opioid analgesics, antipyretics and nonsteroidal antiinflammatorydrugs in children: epidemiology, clinical aspects,pathophysiology, diagnosis and prevention. Arch Pediatr.2012;19:556-60
104. Ponvert C, Scheinmann P. Allergic and pseudoallergicreactions to analgesics, antipyretics and non-steroidal antiinflammatorydrugs. Arch Pediatr. 2007;14:507-12
105. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, Bircher A, Blanca M, Bonadonna B, Campi P, Castro E, Cernadas JR, Chiriac AM, Demoly P, Grosber M, Gooi J, Lombardo C, Mertes PM, Mosbech H, Nasser S, Pagani M, Ring J, Romano A, Scherer K, Schnyder B, Testi S, Torres M, Trautmann A, Terreehorst I, Group EEDAI. Skin test concentrations for systemically administered drugs -an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68:702-12
106. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, Gonzalez G, Dieguez I, De Weck AL. Use of CD63expression as a marker of in vitro basophil activation andleukotriene determination in metamizol allergic patients. Allergy. 2003;58:312-7
107. Barbaud A. Skin testing and patch testing in non-IgE-mediateddrug allergy. Curr Allergy Asthma Rep. 2014;14:442
108. Na HR, Lee JM, Jung JW, Lee SY. Usefulness of drugprovocation tests in children with a history of adverse drugreaction. Korean J Pediatr. 2011;54:304-9
109. Mayorga C, Sanz ML, Gamboa P, Garcia-Aviles MC, Fernandez J, Torres MJ, Spanish Society of A, Clinical, Immunology,Immunology, Drug Allergy C. In vitro methods for diagnosingnonimmediate hypersensitivity reactions to drugs. J InvestigAllergol Clin Immunol. 2013;23:213-25
110. Goncalo M, Ferguson J, Bonevalle A, Bruynzeel DP, Gimenez-Arnau A, Goossens A, Kerr A, Lecha M, Neumann N, NiklassonB, Pigatto P, Rhodes LE, Rustemeyer T, Sarkany R, Thomas P, Wilkinson M. Photopatch testing: recommendations for aEuropean photopatch test baseline series. Contact Dermatitis.2013;68:239-43
111. Steiner M, Harrer A, Lang R, Schneider M, Ferreira T, Hawranek T, Himly M. Basophil activation test for investigation of IgEmediatedmechanisms in drug hypersensitivity. J Vis Exp.2011;55:3263
112. Blanca M, Posadas S, Torres MJ, Leyva L, Mayorga C, Gonzalez L, Juarez C, Fernandez J, Santamaria LF. Expression of theskin-homing receptor in peripheral blood lymphocytes fromsubjects with nonimmediate cutaneous allergic drug reactions.Allergy. 2000;55:998-1004
113. Fernandez J, Blanca M, Moreno F, Garcia J, Segurado E, delCano A, Aguilar F. Role of tryptase, eosinophil cationic proteinand histamine in immediate allergic reactions to drugs. IntArch Allergy Immunol. 1995;107:160-2
114. Yilmaz O, Ertoy Karagol IH, Bakirtas A, Topal E, Celik GE, Demirsoy MS, Turktas I. Challenge-proven nonsteroidalanti-inflammatory drug hypersensitivity in children. Allergy.2013;68:1555-61
115. Lerch M, Pichler WJ. The immunological and clinical spectrumof delayed drug-induced exanthems. Curr Opin Allergy ClinImmunol. 2004;4:411-9
116. Fernandez TD, Canto G, Blanca M. Molecular mechanisms ofmaculopapular exanthema. Curr Opin Infect Dis. 2009;22:272-8
117. Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P, European Network for Drug A, hypersensitivity Eigod. Drug provocation testingin the diagnosis of drug hypersensitivity reactions: generalconsiderations. Allergy. 2003;58:854-63
118. Ordoqui E, De Barrio M, Rodriguez VM, Herrero T, Gil PJ, Baeza ML. Cross-sensitivity among oxicams in piroxicam-causedfixed drug eruption: two case reports. Allergy. 1995;50:741-4
119. Gomez-Traseira C, Rojas-Perez-Ezquerra P, Sanchez-Morillas L, Gonzalez-Mendiola R, Rubio-Perez M, Moral-Morales A, Juliolaguna-Martinez J. Paracetamol-induced fixed drugeruption at an unusual site. Recent Pat Inflamm Allergy DrugDiscov. 2013;7:268-70
120. Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011;127:S67-73
121. Sicherer SH, Sampson HA. Food allergy: Epidemiology,pathogenesis, diagnosis, and treatment. J Allergy ClinImmunol. 2014;133:291-307
122. Hansen RC. Staphylococcal scalded skin syndrome, toxic shocksyndrome, and Kawasaki disease. Pediatr Clin North Am.1983;30:533-44
123. Green D, Law E, Still JM. An approach to the management of toxicepidermal necrolysis in a burn centre. Burns. 1993;19:411-4
124. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnsonsyndrome/toxic epidermal necrolysis. Am J Clin Dermatol.2000;1:349-60
125. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Taieb A. Diagnosis, classification, and management of erythemamultiforme and Stevens-Johnson syndrome. Arch Dis Child.2000;83:347-52
126. Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniaeinfection is associated with Stevens-Johnson syndrome,not erythema multiforme (von Hebra). J Am Acad Dermatol.1996;35:757-60
127. Gonzalez FJ, Carvajal MJ, del Pozo V, Lahoz C, Santamaria L, Blanca M, Juarez C. Erythema multiforme to phenobarbital: involvement of eosinophils and T cells expressing the skinhoming receptor. J Allergy Clin Immunol. 1997;100:135-7
128. Romano A, Blanca M, Torres MJ, Bircher A, Aberer W, Brockow K, Pichler WJ, Demoly P, Enda E . Diagnosis ofnonimmediate reactions to beta-lactam antibiotics. Allergy.2004;59:1153-60
129. Chiriac AM, Demoly P. Multiple drug hypersensitivity syndrome. Curr Opin Allergy Clin Immunol. 2013;13:323-9
130. Sheridan RL, Weber JM, Schulz JT, Ryan CM, Low HM, Tompkins RG. Management of severe toxic epidermal necrolysis inchildren. J Burn Care Rehabil. 1999;20:497-500
131. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC. Characteristics of toxic epidermal necrolysis inpatients undergoing long-term glucocorticoid therapy. ArchDermatol. 1995;131:669-72
132. Goyal S, Gupta P, Ryan CM, Kazlas M, Noviski N, Sheridan RL. Toxic epidermal necrolysis in children: medical, surgical, andophthalmologic considerations. J Burn Care Res. 2009;30:437-49
133. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenousimmunoglobulin in children. J Am Acad Dermatol.2002;47:548-52
134. Koh MJ, Tay YK. Stevens-Johnson syndrome and toxicepidermal necrolysis in Asian children. J Am Acad Dermatol.2010;62:54-60
135. Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics. 2001;108:1162-8
136. Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenousimmunoglobulin and corticosteroid in the treatment oftoxic epidermal necrolysis and Stevens-Johnson syndrome:a retrospective comparative study in China. Int J Dermatol.2009;48:1122-8
137. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy forStevens-Johnson syndrome/toxic epidermal necrolysis. ActaDerm Venereol. 2007;87:144-8
138. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality ofStevens-Johnson syndrome and toxic epidermal necrolysis:A retrospective study on patients included in the prospectiveEuroSCAR Study. J Am Acad Dermatol. 2008;58:33-40
139. French LE, Trent JT, Kerdel FA. Use of intravenousimmunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. IntImmunopharmacol. 2006;6:543-9
140. Mittmann N, Chan B, Knowles S, Cosentino L, Shear N. Intravenous immunoglobulin use in patients with toxicepidermal necrolysis and Stevens-Johnson syndrome. Am JClin Dermatol. 2006;7:359-68
141. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulintreatment for Stevens-Johnson syndrome and toxic epidermalnecrolysis: a prospective noncomparative study showingno benefit on mortality or progression. Arch Dermatol.2003;139:33-6
142. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenousimmunoglobulin does not improve outcome in toxic epidermalnecrolysis. J Burn Care Rehabil. 2004;25:246-55
143. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulinmake a difference? J Burn Care Rehabil. 2004;25:81-8
144. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenousimmunoglobulin in the treatment of Stevens-Johnsonsyndrome and toxic epidermal necrolysis: a meta-analysiswith meta-regression of observational studies. Int J Dermatol.2015;54:108-15
145. Morici MV, Galen WK, Shetty AK, Lebouef RP, Gouri TP, Cowan GS, Gedalia A. Intravenous immunoglobulin therapyfor children with Stevens-Johnson syndrome. J Rheumatol.2000;27:2494-7
146. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacyof low dose intravenous immunoglobulins in children withtoxic epidermal necrolysis: an open uncontrolled study. IndianJ Dermatol Venereol Leprol. 2005;71:398-400
147. Koh MJ, Tay YK. An update on Stevens-Johnson syndromeand toxic epidermal necrolysis in children. Curr Opin Pediatr.2009;21:505-10
148. Inamo Y, Okubo T, Wada M, Fuchigami S, Hashimoto K, Fuchigami T, Takahashi S, Sawada S, Harada K. Intravenousulinastatin therapy for Stevens-Johnson syndrome and toxicepidermal necrolysis in pediatric patients. Three case reports.Int Arch Allergy Immunol. 2002;127:89-94
149. Mayorga C, Torres MJ, Corzo JL, Sanchez-Sabate E, Alvarez J, Vera A, Posadas S, Jurado A, Blanca M. Improvement oftoxic epidermal necrolysis after the early administration of asingle high dose of intravenous immunoglobulin. Ann AllergyAsthma Immunol. 2003;91:86-91
150. Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol. 2012;53:87-92
151. Sultan SJ, Sameem F, Ashraf M. Drug reaction with eosinophiliaand systemic symptoms: manifestations, treatment, andoutcome in 17 patients. Int J Dermatol. 2015;54:537-42
152. Stevenson DD. Aspirin sensitivity and desensitization for asthmaand sinusitis. Curr Allergy Asthma Rep. 2009;9:155-63
153. Castells M. Rapid desensitization for hypersensitivity reactionsto medications. Immunol Allergy Clin North Am. 2009;29:585-606
154. Swierczynska-Krepa M, Sanak M, Bochenek G, Strek P, Cmiel A, Gielicz A, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E. Aspirin desensitization in patients with aspirin-induced andaspirin-tolerant asthma: A double-blind study. J Allergy ClinImmunol. 2014;134:883-90
155. Woessner KM, White AA. Evidence-based approach to aspirindesensitization in aspirin-exacerbated respiratory disease. JAllergy Clin Immunol. 2014;133:286-7
156. Perkins JR, Sanak M, Canto G, Blanca M, Cornejo-Garcia JA. Unravelling adverse reactions to NSAIDs using systemsbiology. Trends Pharmacol Sci. 2015;36:172-80.